These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 34669432)

  • 41. From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life.
    Ray SK; Mukherjee S
    Recent Pat Biotechnol; 2022; 16(1):2-5. PubMed ID: 34886784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. mRNA-based vaccines - global approach, challenges, and could be a promising wayout for future pandemics.
    Makhijani S; Elossaily GM; Rojekar S; Ingle RG
    Pharm Dev Technol; 2024 Jul; 29(6):559-565. PubMed ID: 38814266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Super-rapid race for saving lives by developing COVID-19 vaccines.
    Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
    J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
    Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
    ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The COVID-19 pandemic: viral variants and vaccine efficacy.
    Ciotti M; Ciccozzi M; Pieri M; Bernardini S
    Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative analysis of the effectiveness difference of SARS-COV-2 mRNA vaccine in different populations in the real world: A review.
    Cai S; Chang C; Zhang X; Qiao W
    Medicine (Baltimore); 2023 Aug; 102(34):e34805. PubMed ID: 37653835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Zhang C; Zhou C; Shi L; Liu G
    Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration.
    Vanijcharoenkarn K; Lee FE; Martin L; Shih J; Sexton ME; Kuruvilla ME
    Clin Infect Dis; 2021 Dec; 73(11):2108-2111. PubMed ID: 33989390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of COVID-19 and mRNA vaccines on human fertility.
    Chen F; Zhu S; Dai Z; Hao L; Luan C; Guo Q; Meng C; Zhang Y
    Hum Reprod; 2021 Dec; 37(1):5-13. PubMed ID: 34734259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coronavirus disease 2019 (COVID-19) vaccines: A concise review.
    Samaranayake LP; Seneviratne CJ; Fakhruddin KS
    Oral Dis; 2022 Nov; 28 Suppl 2():2326-2336. PubMed ID: 33991381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines.
    Hofman K; Shenoy GN; Chak V; Balu-Iyer SV
    Immunol Invest; 2021 Oct; 50(7):743-779. PubMed ID: 33929280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward.
    Vashishtha VM; Kumar P
    Hum Vaccin Immunother; 2021 Jun; 17(6):1635-1649. PubMed ID: 33270478
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are We Paving the Way to Dig Out of the "Pandemic Hole"? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization.
    Tardiolo G; Brianti P; Sapienza D; dell'Utri P; Dio VD; Rao G; Calabrò RS
    Med Sci (Basel); 2021 Jul; 9(3):. PubMed ID: 34449681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
    Deng Z; Tian Y; Song J; An G; Yang P
    Front Immunol; 2022; 13():887125. PubMed ID: 35720301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.
    Rouf NZ; Biswas S; Tarannum N; Oishee LM; Muna MM
    RNA Biol; 2022; 19(1):386-410. PubMed ID: 35354425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SARS-CoV-2 Vaccines: Where Are We Now?
    Flanagan KL; MacIntyre CR; McIntyre PB; Nelson MR
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3535-3543. PubMed ID: 34400116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
    Leav B; Straus W; White P; Leav A; Gaines T; Maggiacomo G; Kim D; Smith ER; Gurwith M; Chen RT;
    Vaccine; 2022 Aug; 40(35):5275-5293. PubMed ID: 35753841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.